Marketing authorisation: Splitting the bill
An increasing number of pharmaceutical companies are turning to joint representation—where they pool their funds and hire one firm to represent them all—for ANDA litigation. Mark Remus, shareholder at Brinks Gilson & Lione, outlines the pros and cons of this new direction.
- SPCs: extending protection lifespan 20-05-2019
- The heart of the 3D printing matter 20-05-2019
- Creative solutions for cannabis industry IP 20-05-2019
- Antibody patents: Danger ahead for biologics 20-05-2019
- How to protect therapeutic methods in Brazil 20-05-2019
Latest news
Gilead claims US government PrEP patents are invalid
20-05-2019
Gilead’s CEO has told a US House of Representatives committee that three Centers for Disease Control HIV prevention patents are invalid.
EU adopts SPC manufacturing waiver
16-05-2019
